Proxy Votes Now

Home › Upcoming votes › Lifecore Biomedical, Inc.

Lifecore Biomedical, Inc. Special Meeting December 23, 2026: What's on the Ballot

Merger or special meeting

Prior-year votes at Lifecore Biomedical, Inc. →

The deadline as the proxy statement states it: “instructions detailed in the section of this proxy statement entitled "The Special Meeting-Voting Procedures", so long as your later-dated proxy is received by 11:59 p.m., Eastern Time, on December 22, 2026”. Shares held through a bank, a broker or a company plan can have a different deadline; the voting instruction form says.

Read the proxy statement on EDGARLifecore Biomedical, Inc.: past votes

Proxy summary

Summary, checked against the proxy statement. Each point is backed by a passage of the filing, shown under the point; figures under “Last year’s votes” come from the company’s Form 8-K. Read the proxy statement before relying on it.

Special meeting to vote on the merger with affiliates of Webster Equity Partners, an advisory vote on merger-related executive pay, and a possible adjournment.

Key points

Last year’s votes

What’s on the ballot

Ballot read from the proxy statement and checked. As listed in Lifecore Biomedical, Inc.’s proxy statement, with the board’s recommendation on each item.

#ItemProposed byBoard recommendsLast year (same kind of item)
1 MERGER AGREEMENT PROPOSAL Board For —
2 ADVISORY COMPENSATION PROPOSAL Board For —
3 ADJOURNMENT PROPOSAL
Adjournment
Board For —

Last year’s official results

From Lifecore Biomedical, Inc.’s Form 8-K, filed October 31, 2025, for the meeting held October 29, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.

ItemSupport (of votes cast)Reported outcome
Elect Director: Katrina L. Houde90%—
Elect Director: Humberto C. Antunes99.0%—
Elect Director: Paul H. Johnson99.5%—
Elect Director: Paul Josephs99.8%—
Elect Director: Matthew E. Korenberg95%—
Elect Director: Nelson Obus98%—
Elect Director: Joshua E. Schechter89%—
Elect Director: Jason Aryeh——
Elect Director: Christopher S. Kiper——
2. The appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, 99.9%Approved
3. The compensation paid to the Company's named executive officers (in the form of a non-binding, advisory vote), with votes99.0%Approved

How the largest managers voted here last year

The five managers that reported the most shares voted at Lifecore Biomedical, Inc.’s October 29, 2025 meeting, from their Form N-PX filings. This is how they voted then; it says nothing about how they will vote this time. Every manager’s vote.

ItemWYNNEFIELD CAPITAL INCLegion Partners Asset Management, LLC325 CAPITAL LLCVanguardBlackRock
Elect Director: Katrina L. Houde———ForAgainst
Elect Director: Humberto C. Antunes———ForFor
Elect Director: Paul H. Johnson———ForFor
Elect Director: Paul Josephs———ForFor
Elect Director: Matthew E. Korenberg———ForFor
Elect Director: Nelson Obus———ForFor
Elect Director: Joshua E. Schechter———ForAgainst
2. The appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending———ForFor
3. The compensation paid to the Company's named executive officers (in the form of a non-binding, advisory vote), with vFor—ForForFor
PROPOSAL NO LONGER VALID————Abstain

Filings for this meeting

About this page

The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.